scholarly journals Effect of a low dose of alloxan on blood glucose, islet beta cell granulation, body weight, and insulin resistance of ob/ob mice

Diabetologia ◽  
1974 ◽  
Vol 10 (6) ◽  
pp. 709-715 ◽  
Author(s):  
J. Solomon ◽  
R. J. Bulkley ◽  
J. Mayer
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Blood Glucose ◽  
Beta Cell ◽  
Low Dose ◽  
Islet Beta Cell

scholarly journals PEX-168 Improves Insulin Resistance, Inflammatory Response and Adipokines in Simple Obese Mice and Explore the Mechanism

2021 ◽  
Author(s):  
Guo Zeyuan ◽  
Wu Yuting ◽  
Sun Xiaofang
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Blood Glucose ◽  
Statistical Difference ◽  
Low Dose ◽  
Control Group ◽  
Obese Mice ◽  
Inflammatory Status ◽  
Short Period ◽  
Different Doses

Abstract Background: Polyethylene glycxol losenatide（PEX-168）is a new anti-diabetic drug and there are no reports on its weight loss effects，so we designed this trial to investigate the effect of PEX-168 on simple obese mice. Methods: Thirty healthy C57BL/6 male mice were randomly selected and divided into a blank control group (NC, n=6) and an obesity model group (n=24), the high-fat diet-induced simple obesity mice were divided into a model control group (HF) and three different doses of PEX-168 intervention groups of low (LD), medium (MD) and high (HD) (the doses of PEX-168 were 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg), 6 animals in each group. The intervention groups were injected with different doses of PEX-168 intraperitoneally once a week for 12 weeks, and fasting blood glucose (FBG), body weight and food intake were measured from 1 to 12 weeks after the injection, and the activity of mice was observed, and serum insulin (INS), CRP, chemerin and omentin levels were measured after 12 weeks. Results: Compared with the HF group, the low dose of PEX-168 could reduce the body weight of mice in a short period of time (8 weeks), and the mice in the LD and HD groups had a significant decrease in body weight (P < 0.05)；the low dose of PEX-168 could effectively improve the blood glucose and Homa-IR of mice (FBG P < 0.05 INS, IR P < 0.001), but there was no statistical difference between different doses (P > 0.05)；CRP levels in HD and LD groups were significantly improved(P < 0.05)，the levels of serum chemerin and omentin in intervention groups were significantly improved (P < 0.01), but there was no statistical difference between the different doses (P > 0.05). Conclusion: Continuous 12W administration of PEX-168 significantly reduced body weight in simple obese mice, thereby improving inflammatory status, improving insulin resistance, reducing serum chemerin level and increasing serum omentin level, inhibiting the development of diabetes. PEX-168 may regulate the expression of chemerin and omentin mainly through its hypoglycemic effect.

scholarly journals PEX-168 Improves Insulin Resistance, Inflammatory Response and Adipokines in Simple Obese Mice: A Mechanistic Exploration

2021 ◽  
Author(s):  
Zeyuan Guo ◽  
Yuting Wu ◽  
Xiaofang Sun
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Blood Glucose ◽  
Low Dose ◽  
The Body ◽  
Control Group ◽  
Obese Mice ◽  
Short Period ◽  
Significant Difference ◽  
Different Doses

Abstract Background：Polyethylene glycol losenatide (PEX-168) is a new antidiabetic drug; as such, there are not yet any reports on its weight loss effect. Therefore, this trial was designed to investigate the effect of PEX-168 on simple obese mice.Methods：Thirty healthy male C57BL/6 mice were randomly selected and divided into a control group (NC) and an obesity model group. The high-fat diet-induced simple obesity mice were divided into a model control group (HF) and three intervention groups. The intervention groups were injected with different doses of PEX-168 intraperitoneally once a week for 12 weeks (low (LD), medium (MD) and high (HD)). Fasting blood glucose (FBG), body weight and food intake were measured from 1 to 12 weeks after PEX-168 injection. The serum insulin (INS), C-reactive protein (CRP), chemerin and omentin levels were measured after 12 weeks.Results：Compared with the HF group, the low dose of PEX-168 reduced the body weight of the mice in a short period of time (8 weeks), and the mice in the LDand HD groups showed a significant decrease in body weight (P < 0.05). The low dose of PEX-168 could effectively improve the blood glucose and insulin resistance index (Homa-IR) of the mice (FBG P < 0.05 INS, Homa-IR P < 0.001), but there was no significant difference between different doses (P > 0.05). CRP levels in the HD and LD groups were significantly improved (P < 0.05). The levels of serum chemerin and omentin in the intervention groups were also significantly improved (P < 0.01), but there was no significant difference between the different doses (P > 0.05).Conclusion：PEX-168 significantly reduced the body weight of simple obese mice and prevented the development of diabetes. PEX-168 may regulate the expression of chemerin and omentin mainly through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both.

scholarly journals PEX-168 Improves Insulin Resistance, Inflammatory Response and Adipokines in Simple Obese Mice: A Mechanistic Exploration

2021 ◽  
Author(s):  
Zeyuan Guo ◽  
Yuting Wu ◽  
Sun Xiaofang
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Blood Glucose ◽  
Low Dose ◽  
The Body ◽  
Control Group ◽  
Obese Mice ◽  
Short Period ◽  
Significant Difference ◽  
Different Doses

Abstract Background: Polyethylene glycol losenatide (PEX-168) is a new antidiabetic drug; as such, there are not yet any reports on its weight loss effect. Therefore, this trial was designed to investigate the effect of PEX-168 on simple obese mice.Methods: Thirty healthy male C57BL/6 mice were randomly selected and divided into a control group (NC, n=6) and an obesity model group (n=24). The high-fat diet-induced simple obesity mice were divided into a model control group (HF) and three intervention groups receiving different doses of PEX-168 (low (LD), medium (MD) and high (HD), receiving PEX-168 doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, respectively), with 6 animals in each group. The intervention groups were injected with different doses of PEX-168 intraperitoneally once a week for 12 weeks. Fasting blood glucose (FBG), body weight and food intake were measured from 1 to 12 weeks after PEX-168 injection. The activity of the mice was observed, and serum insulin (INS), C-reactive protein (CRP) chemerin and omentin levels were measured after 12 weeks.Results: Compared with the HF group, the low dose of PEX-168 reduced the body weight of the mice in a short period of time (8 weeks), and the mice in the LD and HD groups showed a significant decrease in body weight (P < 0.05). The low dose of PEX-168 could effectively improve the blood glucose and insulin resistance index (Homa-IR) of the mice (FBG P < 0.05 INS, Homa-IR P < 0.001), but there was no significant difference between different doses (P > 0.05). CRP levels in the HD and LD groups were significantly improved (P < 0.05). The levels of serum chemerin and omentin in the intervention groups were also significantly improved (P < 0.01), but there was no significant difference between the different doses (P > 0.05).Conclusion: PEX-168 significantly reduced the body weight of simple obese mice and prevented the development of diabetes. PEX-168 may regulate the expression of chemerin and omentin mainly through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both.

scholarly journals PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zeyuan Guo ◽  
Yuting Wu ◽  
Lihua Zhu ◽  
Yong Wang ◽  
Daorong Wang ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Blood Glucose ◽  
Low Dose ◽  
The Body ◽  
Control Group ◽  
Obese Mice ◽  
Short Period ◽  
Significant Difference ◽  
Different Doses

Abstract Background Polyethylene glycol loxenatide (PEX-168) is a new antidiabetic drug; as such, there are not yet any reports on its weight loss effect. Therefore, this trial was designed to investigate the effect of PEX-168 on simple obese mice. Methods Thirty healthy male C57BL/6 mice were randomly selected and divided into a control group (NC) and an obesity model group. The high-fat diet-induced simple obesity mice were divided into a model control group (HF) and three intervention groups. The intervention groups were injected with different doses of PEX-168 intraperitoneally once a week for 12 weeks (low (LD), medium (MD) and high (HD)). Fasting blood glucose (FBG), body weight and food intake were measured from 1 to 12 weeks after PEX-168 injection. The serum insulin (INS), C-reactive protein (CRP), chemerin and omentin levels were measured after 12 weeks. Results Compared with the HF group, the low dose of PEX-168 reduced the body weight of the mice in a short period of time (8 weeks), and the mice in the MD and HD groups showed a significant decrease in body weight (P < 0.05). The low dose of PEX-168 could effectively improve the blood glucose and homeostasis model assessment of insulin resistance (Homa-IR) of the mice (FBG P < 0.05 INS, Homa-IR P < 0.001), but there was no significant difference between different doses (P > 0.05). CRP levels in the MD and HD groups were significantly improved (P < 0.05). The levels of serum chemerin and omentin in the intervention groups were also significantly improved (P < 0.01), but there was no significant difference between the different doses (P > 0.05). Conclusions PEX-168 significantly reduced the body weight of simple obese mice and improved the insulin resistance. PEX-168 may regulate the expression of chemerin and omentin through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both.

scholarly journals Hypoglycemic Effect of Vitexin in C57BL/6J Mice and HepG2 Models

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Weidong Xu ◽  
Jiayao Li ◽  
Weipeng Qi ◽  
Ye Peng
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Weight Gain ◽  
Blood Glucose ◽  
Glucose Uptake ◽  
Lipid Content ◽  
Hepg2 Cells ◽  
Body Weight Gain ◽  
Tnf Α ◽  
Hepatic Lipid Content

Apigenin-8-C-glucoside (vitexin), a natural phytochemical contained in hawthorn, has been reported to have versatile beneficial bioactivities, such as antioxidation, anticancer property, and adipogenesis inhibition. The present research aimed to determine the influence of vitexin on insulin resistance elicited by HFD in mice and HepG2 cells. Vitexin markedly alleviated body weight gain and improved glucose and insulin intolerance induced by HFD. Vitexin partially normalized blood glucose, cholesterol, TNF-α, and hepatic lipid content. Moreover, vitexin recovered the reduced glucose uptake induced by glucosamine. The present results indicate that vitexin prevents HFD-induced insulin resistance.

scholarly journals EFFECT OF ALOE BARBADENSIS MILLER WHOLE LEAF EXTRACT ON HYPERGLYCEMIA AND INSULIN RESISTANCE IN LOW DOSE STREPTOZOTOCIN INDUCED TYPE 2 DIABETIC RATS

1969 ◽  
Vol 3 (2) ◽  
pp. 350-355
Author(s):  
MEENA GUL ◽  
MUHAMMAD MAZHAR HUSSAIN ◽  
AYESHA BABER ◽  
AMJAD ZAMAN ◽  
MUSRAT ZAHRA
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Plasma Glucose ◽  
Leaf Extract ◽  
Low Dose ◽  
Aloe Vera ◽  
Control Group ◽  
Sprague Dawley ◽  
Type 2 Diabetic

BACKGROUND: Managing diabetes is difficult due to the number of side effects associated with drugsused for its treatment. There it is a need of an hour to look for indigenous plants which are safe and costeffective. Present study was planned to determine the effect of Aloe vera whole leaf extract and/orRosiglitazone on plasma glucose, insulin and insulin resistance in type 2 diabetic Sprague-Dawley rats.DESIGN: Randomized control trailPLACE AND DURATION OF STUDY: This study was conducted from April 2009 to Oct 2010 at theDepartment of Physiology Army Medical College, Rawalpindi in collaboration with National Institute ofHealth (NIH) Islamabad.MATERIAL AND METHOD: Type 2 DM was induced in 60 healthy Sprague-Dawley rats by feedinghigh fat diet for 2 weeks and injecting a low dose (35mg/kg) of streptozotocin intra peritoneally. Type 2diabetic rats were randomly divided into four groups, each group having 15 rats and were labeled as diabeticgroup, Aloe vera group, rosiglitazone group and combined group. The diabetic group was injected normalsaline, Aloe vera group was treated with Aloe vera whole leaf extract in dose of 300mg/kg body weight,rosiglitazone group was given 5mg/kg body weight of rosiglitazone I/P and combined group diabetic ratswere treated with 150mg/kg body weight of Aloevera extract and 2.5mg/kg body weight of rosiglitazone(halfof their effective dose) for 21 days.RESULTS: A significant reduction (p<0.001) in plasma glucose (73%), insulin (32%) and TG/HDL ratio(81%) was analyzed in combined groupascompared to diabetic control group. \CONCLUSION: The maximum impact in lowering plasma glucose, insulin and TG/HDL ratio wasrecorded in combined group, followed by rosiglitazone group and then Aloevera group.KEYWORDS:T2DM. Aloe vera, insulin resistance

Autoimmunity, Insulin Resistance and Beta Cell Function in Subjects with Low Body Weight Type 2 Diabetes Mellitus

2007 ◽  
Vol 5 (2) ◽  
pp. 136-141 ◽  
Author(s):  
Sidhartha Das ◽  
Sanjeev Kumar Bhoi ◽  
A.K. Baliarsinha ◽  
Mirza Asraf Ali Baig
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function

scholarly journals Amisulpride - An Athypical Antipsychotic?

2015 ◽  
Vol 61 (4) ◽  
pp. 337-341
Author(s):  
Echim George ◽  
Sorina Cucuiet ◽  
Bianca Osz ◽  
Alexandra Grosan ◽  
Gal Zsolt ◽  
...  
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Biochemical Parameters ◽  
Low Dose ◽  
Body Weight Gain ◽  
Control Group ◽  
Initial Weight ◽  
Glucose Levels ◽  
Blood Glucose Concentrations ◽  
Different Doses

AbstractAim: the purpose of the present study was to determine the effects of amisulpride at different doses on body weight, glucidic and lipidic metabolism.Material and method: Thirty-six white Wistar rats were treated daily for 9 weeks with amisulpride 1mg/kg and 10mg/kg body weight. Another group received distilled water and served as control group. At the end of the treatment period blood samples were collected and the follow biochemical parameters were determined: serum cholesterol, triglycerides, blood glucose, GOT, GPT. Body weight gain was also assessed weekly.Results: After treatment with amisulpride in doses of 1mg/kg and 10 mg/kg for a period of nine weeks, weight gains were recorded for both groups compared with the initial weight and the control group. Blood glucose concentrations in the group treated with 1 mg amisulpride/kg body weight were significantly increased (p<0.05 vs control group), but in the group treated with 10 mg/kg body weight glucose levels were not statistically significant increased compared to controls. Other biochemical parameters (cholesterol, triglycerides, GOT, GPT) showed no statistically significant differences compared to control group.Conclusions: amisulpride administered over a period of 9 weeks, in doses of 1mg/kg and 10mg/kg showed a slight increase of body weight regardless of gender, increased blood glucose only when was administered in the low dose, and does not affect lipid metabolism, even though decreased cholesterol and triglycerides levels. This results highlight a real benefit of treatment with amisulpride, comparatively with other athypical antipsychotics.

Sign in / Sign up

Export Citation Format

Share Document